Sorafenib inhibits RAF kinase, VEGFR, and PDGFR concurrently, and is predominantly used for hepatocellular carcinoma and renal cell carcinoma (105, 106). This evidence concerns the gene KDR and hereditary clear cell renal cell carcinoma.